Abbott Laboratories with ticker code (ABT) have now 20 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $133.00 and $100.00 calculating the mean target price we have $116.40. Now with the previous closing price of $107.25 this would imply there is now a potential upside of 8.5%. The 50 day moving average now sits at $98.13 and the 200 day MA is $103.01. The market cap for the company is 188.54B. The stock price is currently at: $108.60 USD
The potential market cap would be $204,621,010,093 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 36.94, revenue per share of $22.95 and a 5.72% return on assets.
Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women’s health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
